Table 6.

Cox proportional hazard modelling of UBE2O after accounting for clinical recurrence free survival—173 from 335 patients with prostate cancer could be evaluated for survival.

	Univariate				Multivariate
	HR	Lower	Upper	p-Value	HR	Lower	Upper	p-Value
Age	1.074	0.976	1.182	0.142
Height	0.936	0.854	1.026	0.155	1.276	1.134	1.435	<0.001
Weight	0.933	0.875	0.995	0.036	0.807	0.710	0.918	<0.001
Adjuvant treatment: no	Reference
Adjuvant treatment: yes	19.624	2.544	151.376	0.004
UBE2O grade 1	Reference
UBE2O grade 2	1.356	0.151	12.169	0.786	0.028	0.008	0.106	<0.001
UBE2O grade 3	1.644	0.191	14.150	0.651	0.023	0.006	0.084	<0.001
PSA grade 0	Reference
PSA grade 1	2.473	0.715	8.546	0.153	6.938	1.847	26.064	0.004
PSA grade 2	1.798	0.429	7.537	0.422	0.213	0.027	1.708	0.145
Gleason score grade 0
Gleason score grade 1
Gleason score grade 2
Pathologic T stage grade 0	Reference
Pathologic T stage grade 1	4.154	1.272	13.562	0.018
Seminal vesicle invasion: negative	Reference
Seminal vesicle invasion: positive	5.392	1.735	16.756	0.004
Regional lymph node: negative	Reference
Regional lymph node: positive	12.474	3.933	39.567	<0.001	90.544	22.747	360.410	<0.001
Surgical margin: negative	Reference
Surgical margin: positive	3.169	0.967	10.381	0.057

UBE2O grade—0: negative, 1: weak, 2: moderate, 3: strong. PSA grade 0: PSA < 10 ng/mL, 1: PSA 10–20 ng/mL, 2: PSA > 20 ng/mL. Gleason score grade—0: Gleason score ≤ 6, 1: Gleason score 7, 2: Gleason score ≥ 8. Pathologic T stage grade—0: ≤T2, 1: ≥T3.